- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01501474
Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
- To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
- To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Study Overview
Status
Conditions
Detailed Description
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
- To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
- To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Inclusion Criteria
- Age > 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form Exclusion Criteria
1.Cannot follow up for 1 year 2.Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants 3.Pregnancy 4.History of fluorescein allergy
Timeline: From January 2012 to December 2013
Sample size Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients
Method
- All patients had informed the consent.
- Take the history, physical examination and then fill in the record form 3.5 ml of blood sampling for CA19-9 and 20 ml for further test by keeping in -20c temperature for 5 years
4.Set confocal endomicroscopy at the same session of ERCP 5.After successfully cannulation;
- 10% Fluorescein sodium 2.5 ml was injected intravenously.
Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder.
6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;
- Thick branching bands (>20 microns)
- Dark clumps or glands (usually measuring > 60 microns)
Bright and tortuous vessels
Follow up
- The patients who are diagnosed malignant biliary obstruction will be treated as standard management
- The patients who are not diagnosed malignant biliary obstruction will be followed up every 3 months for 1 year
- The gold standard is pathology or clinical of malignancy including evidence of metastasis.
Statistical analysis Sensitivity, specificity, negative predictive value(NPV), positive predictive value(PPV) and accuracy by McNemar's test
Ethical considerations There is not a clearly evidence about the significant serious side effect of fluorescein injection. If the patients have side effects during the research, the procedure will be terminated and the patients will be in the responsibility of all investigators.
Expected benefit and application
- Increase rate of malignant biliary stricture diagnosis by using CholangioFlex and/or FISH test
- Decrease the mortality rate of malignant biliary stricture
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10330
- Rapat Pittayanon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form
Exclusion Criteria:
- Cannot follow up for 1 year
- Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants
- Pregnancy
- History of fluorescein allergy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
CholangioFlex and Fluorescent in situ Hybridization(FISH)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increasing the detection rate of malignant biliary stricture diagnosis by using CholangioFlex (Cofocal) and/or FISH test
Time Frame: up to 1 year
|
If investigator can detect malignant biliary stricture more than present, the care giver can treat these patients properly.
Consequently, the mortality rate of malignant biliary stricture will be decrease.
|
up to 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rapat Pittayanon, MD, Chulalongkorn Hospital
- Study Director: Rungsun Rerknimitr, Professor, Chulalongkorn Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Biliary Strictures
-
Catholic University of the Sacred HeartCompletedMalignant Biliary StricturesItaly
-
The Cleveland ClinicCompletedPancreatic Duct Strictures | Biliary Duct StricturesUnited States
-
Boston Scientific CorporationCompletedBiliary Strictures Caused by Malignant NeoplasmsItaly, Belgium, France, Germany, India, Netherlands
-
University of FloridaCompletedBenign Biliary StricturesUnited States
-
Institut Paoli-CalmettesUnknown
-
Boston Scientific CorporationCompleted
-
W.L.Gore & AssociatesCompletedBiliary StricturesGermany
-
National Taiwan University HospitalUnknown
-
University of California, Los AngelesBoston Scientific CorporationRecruitingBenign Biliary Strictures With Current or Prior Biliary ObstructionUnited States
-
University Hospital, GhentCompletedBiliary Strictures Post Liver TransplantationBelgium